Publications

Filters: First Letter Of Last Name is D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Research Design
Ding, Jieli, Tsui-Shan Lu, Jianwen Cai, and Haibo Zhou. "Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Ruppert, A S., J Yin, M Davidian, A A. Tsiatis, J C. Byrd, J A. Woyach, and S J. Mandrekar. "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
Nguyen, Crystal T., Daniel J. Luckett, Anna R. Kahkoska, Grace E. Shearrer, Donna Spruijt-Metz, Jaimie N. Davis, and Michael R. Kosorok. "Estimating individualized treatment regimes from crossover designs." Biometrics 76, no. 3 (2020): 778-788.
Deng, Qiqi, Ying-Ying Zhang, Dooti Roy, and Ming-Hui Chen. "Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
Response Evaluation Criteria in Solid Tumors
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Retreatment
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Retrospective Studies
Ding, Jieli, Tsui-Shan Lu, Jianwen Cai, and Haibo Zhou. "Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Risk Assessment
Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
Zeng, Donglin, Ming-Hui Chen, Joseph G. Ibrahim, Rachel Wei, Beiying Ding, Chunlei Ke, and Qi Jiang. "A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
DE Castro, Mário, Ming-Hui Chen, and Yuanye Zhang. "Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
Risk Factors
Hess, Connie N., Phillip J. Schulte, Kristin L Newby, Philippe Gabriel Steg, Anthony J. Dalby, Marc J. Schweiger, Basil S. Lewis, Paul W. Armstrong, Robert M. Califf, Frans van de Werf et al. "Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
Deng, Yu, Donglin Zeng, Jinying Zhao, and Jianwen Cai. "Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
RNA, Messenger
Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, Ivo D. Shterev, Jiaxing Lin, Yoichi Furukawa et al. "Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
RNA, Small Interfering
Lin, Jiaxing, Jeremy Gresham, Tongrong Wang, So Young Kim, James Alvarez, Jeffrey S. Damrauer, Scott Floyd, Joshua Granek, Andrew Allen, Cliburn Chan et al. "bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens." Bioinformatics 34, no. 20 (2018): 3581-3583.
Sample Size
Molenberghs, Geert, Michael G. Kenward, Marc Aerts, Geert Verbeke, Anastasios A. Tsiatis, Marie Davidian, and Dimitris Rizopoulos. "On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data." Stat Methods Med Res 23, no. 1 (2014): 11-41.
Laber, Eric B., Ying-Qi Zhao, Todd Regh, Marie Davidian, Anastasios Tsiatis, Joseph B. Stanford, Donglin Zeng, Rui Song, and Michael R. Kosorok. "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
Diao, Guoqing, Donglin Zeng, Joseph G. Ibrahim, Alan Rong, Oliver Lee, Kathy Zhang, and Qingxia Chen. "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
Ruppert, A S., J Yin, M Davidian, A A. Tsiatis, J C. Byrd, J A. Woyach, and S J. Mandrekar. "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
Sarcoma
Wisdom, Amy J., Yvonne M. Mowery, Cierra S. Hong, Jonathon E. Himes, Barzin Y. Nabet, Xiaodi Qin, Dadong Zhang, Lan Chen, Hélène Fradin, Rutulkumar Patel et al. "Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
Schizophrenia
Butler, Emily L., Eric B. Laber, Sonia M. Davis, and Michael R. Kosorok. "Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules." Biometrics 74, no. 1 (2018): 18-26.
Selection Bias
Yuan, Shuai, Hao Helen Zhang, and Marie Davidian. "Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
Sensitivity and Specificity
Thomas, Laine, Leonard Stefanski, and Marie Davidian. "A moment-adjusted imputation method for measurement error models." Biometrics 67, no. 4 (2011): 1461-70.
Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
DE Castro, Mário, Ming-Hui Chen, and Yuanye Zhang. "Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
Sequence Analysis, RNA
Van den Berge, Koen, Fanny Perraudeau, Charlotte Soneson, Michael I. Love, Davide Risso, Jean-Philippe Vert, Mark D. Robinson, Sandrine Dudoit, and Lieven Clement. "Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
Signal Transduction
Yu, Fang, Ming-Hui Chen, Lynn Kuo, Heather Talbott, and John S. Davis. "Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
Single-Cell Analysis
Van den Berge, Koen, Fanny Perraudeau, Charlotte Soneson, Michael I. Love, Davide Risso, Jean-Philippe Vert, Mark D. Robinson, Sandrine Dudoit, and Lieven Clement. "Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
Wisdom, Amy J., Yvonne M. Mowery, Cierra S. Hong, Jonathon E. Himes, Barzin Y. Nabet, Xiaodi Qin, Dadong Zhang, Lan Chen, Hélène Fradin, Rutulkumar Patel et al. "Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
Small Cell Lung Carcinoma
Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara et al. "Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara et al. "Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
Software
Van den Berge, Koen, Fanny Perraudeau, Charlotte Soneson, Michael I. Love, Davide Risso, Jean-Philippe Vert, Mark D. Robinson, Sandrine Dudoit, and Lieven Clement. "Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
Lin, Jiaxing, Jeremy Gresham, Tongrong Wang, So Young Kim, James Alvarez, Jeffrey S. Damrauer, Scott Floyd, Joshua Granek, Andrew Allen, Cliburn Chan et al. "bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens." Bioinformatics 34, no. 20 (2018): 3581-3583.
Species Specificity
Blau, S R., L M. Davis, A M. Gorney, C S. Dohse, K D. Williams, J-H Lim, W G. Pfitzner, E Laber, G S. Sawicki, and N J. Olby. "Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
Blau, S R., L M. Davis, A M. Gorney, C S. Dohse, K D. Williams, J-H Lim, W G. Pfitzner, E Laber, G S. Sawicki, and N J. Olby. "Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
Spinal Cord Injuries
Blau, S R., L M. Davis, A M. Gorney, C S. Dohse, K D. Williams, J-H Lim, W G. Pfitzner, E Laber, G S. Sawicki, and N J. Olby. "Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
Blau, S R., L M. Davis, A M. Gorney, C S. Dohse, K D. Williams, J-H Lim, W G. Pfitzner, E Laber, G S. Sawicki, and N J. Olby. "Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
Squamous Cell Carcinoma of Head and Neck
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Statistical Distributions
Tsiatis, Anastasios A., Marie Davidian, and Weihua Cao. "Improved doubly robust estimation when data are monotonely coarsened, with application to longitudinal studies with dropout." Biometrics 67, no. 2 (2011): 536-45.
Statistics, Nonparametric
Yuan, Shuai, Hao Helen Zhang, and Marie Davidian. "Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
Vock, David M., Marie Davidian, Anastasios A. Tsiatis, and Andrew J. Muir. "Mixed model analysis of censored longitudinal data with flexible random-effects density." Biostatistics 13, no. 1 (2012): 61-73.
Daniel, Rhian M., and Anastasios A. Tsiatis. "Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
Stomach Neoplasms
Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
Support Vector Machine
Hager, Rebecca, Anastasios A. Tsiatis, and Marie Davidian. "Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
Surveys and Questionnaires
Butler, Emily L., Eric B. Laber, Sonia M. Davis, and Michael R. Kosorok. "Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules." Biometrics 74, no. 1 (2018): 18-26.
Survival Analysis
Zhang, Min, Anastasios A. Tsiatis, Marie Davidian, Karen S. Pieper, and Kenneth W. Mahaffey. "Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
Zeng, Donglin, Ming-Hui Chen, Joseph G. Ibrahim, Rachel Wei, Beiying Ding, Chunlei Ke, and Qi Jiang. "A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
DE Castro, Mário, Ming-Hui Chen, and Yuanye Zhang. "Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara et al. "Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara et al. "Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Hager, Rebecca, Anastasios A. Tsiatis, and Marie Davidian. "Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
DE Castro, Mário, Ming-Hui Chen, Yuanye Zhang, and Anthony V. D'Amico. "A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
DE Castro, Mário, Ming-Hui Chen, Yuanye Zhang, and Anthony V. D'Amico. "A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
Survival Rate
Vock, David M., Anastasios A. Tsiatis, Marie Davidian, Eric B. Laber, Wayne M. Tsuang, Ashley Finlen C Copeland, and Scott M. Palmer. "Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Secord, Angeles Alvarez, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, Chris J Brady, Heather A. Lankes, Herbert I. Hurwitz et al. "Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
Symposium I
Davidian, Marie. A robust method for estimating optimal treatment regimes., 2011.
Taxoids
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Thioguanine
Appell, Malin L., Jonathan Berg, John Duley, William E. Evans, Martin A. Kennedy, Lynne Lennard, Tony Marinaki, Howard L. McLeod, Mary V. Relling, Elke Schaeffeler et al. "Nomenclature for alleles of the thiopurine methyltransferase gene." Pharmacogenet Genomics 23, no. 4 (2013): 242-8.
Thrombocytopenia
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Time Factors
Daniel, Rhian M., and Anastasios A. Tsiatis. "Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
Zeng, Donglin, Emil Cornea, Jun Dong, Jean Pan, and Joseph G. Ibrahim. "Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
Yu, Fang, Ming-Hui Chen, Lynn Kuo, Heather Talbott, and John S. Davis. "Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Tissue and Organ Procurement
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Tissue Donors
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Trastuzumab
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Treatment Outcome
Zhang, Baqun, Anastasios A. Tsiatis, Eric B. Laber, and Marie Davidian. "A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
Zhang, Min, Anastasios A. Tsiatis, Marie Davidian, Karen S. Pieper, and Kenneth W. Mahaffey. "Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
Hess, Connie N., Phillip J. Schulte, Kristin L Newby, Philippe Gabriel Steg, Anthony J. Dalby, Marc J. Schweiger, Basil S. Lewis, Paul W. Armstrong, Robert M. Califf, Frans van de Werf et al. "Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
DE Castro, Mário, Ming-Hui Chen, and Yuanye Zhang. "Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
Butler, Emily L., Eric B. Laber, Sonia M. Davis, and Michael R. Kosorok. "Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules." Biometrics 74, no. 1 (2018): 18-26.
Diao, Guoqing, Donglin Zeng, Joseph G. Ibrahim, Alan Rong, Oliver Lee, Kathy Zhang, and Qingxia Chen. "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Tumor Escape
Wisdom, Amy J., Yvonne M. Mowery, Cierra S. Hong, Jonathon E. Himes, Barzin Y. Nabet, Xiaodi Qin, Dadong Zhang, Lan Chen, Hélène Fradin, Rutulkumar Patel et al. "Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
Tumor Microenvironment
Wisdom, Amy J., Yvonne M. Mowery, Cierra S. Hong, Jonathon E. Himes, Barzin Y. Nabet, Xiaodi Qin, Dadong Zhang, Lan Chen, Hélène Fradin, Rutulkumar Patel et al. "Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
Tumor Suppressor Protein p53
Jusakul, Apinya, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng et al. "Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
Jusakul, Apinya, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng et al. "Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
United States
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.

Pages